Your browser is no longer supported. Please, upgrade your browser.
UMRX Unum Therapeutics Inc. daily Stock Chart
Unum Therapeutics Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own- Shs Outstand30.14M Perf Week646.40%
Market Cap112.61M Forward P/E- EPS next Y-0.24 Insider Trans- Shs Float26.37M Perf Month429.08%
Income-26.20M PEG- EPS next Q-0.21 Inst Own24.40% Short Float1.58% Perf Quarter850.20%
Sales26.50M P/S4.25 EPS this Y24.70% Inst Trans0.36% Short Ratio0.15 Perf Half Y256.22%
Book/sh0.85 P/B3.91 EPS next Y52.00% ROA-48.70% Target Price4.00 Perf Year41.28%
Cash/sh- P/C- EPS next 5Y- ROE-83.40% 52W Range0.29 - 3.72 Perf YTD360.98%
Dividend- P/FCF- EPS past 5Y- ROI-101.20% 52W High-15.30% Beta-
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low968.14% ATR0.37
Employees72 Current Ratio3.40 Sales Q/Q125.80% Oper. Margin- RSI (14)88.94 Volatility97.52% 30.96%
OptionableNo Debt/Eq0.00 EPS Q/Q48.00% Profit Margin-99.10% Rel Volume2.04 Prev Close3.32
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.71M Price3.15
Recom2.00 SMA20197.06% SMA50331.53% SMA200296.95% Volume1,359,330 Change-5.09%
Mar-04-20Downgrade Wedbush Outperform → Neutral
Mar-03-20Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-20-18Initiated H.C. Wainwright Buy $18
Jul-10-20 08:58AM  
Jul-09-20 09:52AM  
Jul-08-20 08:45AM  
Jul-06-20 10:16AM  
Jun-15-20 07:00AM  
May-28-20 09:54AM  
May-11-20 07:05PM  
Apr-28-20 12:51PM  
Mar-26-20 08:45AM  
Mar-20-20 07:30AM  
Mar-19-20 12:30PM  
Mar-02-20 08:45AM  
Jan-29-20 07:05AM  
Jan-17-20 01:56PM  
Dec-22-19 05:09PM  
Dec-07-19 02:45PM  
Nov-15-19 07:30AM  
Nov-12-19 06:15PM  
Nov-05-19 08:30AM  
Nov-04-19 04:00PM  
Oct-03-19 02:26PM  
Oct-02-19 07:05AM  
Sep-03-19 02:21PM  
Aug-26-19 07:05AM  
Aug-20-19 12:54AM  
Aug-12-19 05:25PM  
Aug-02-19 09:00AM  
Jul-31-19 02:08PM  
Jul-29-19 01:26PM  
Jul-19-19 07:44AM  
Jul-17-19 09:00AM  
Jul-03-19 10:43AM  
Jul-02-19 04:30PM  
Jun-13-19 06:06PM  
May-25-19 01:25AM  
May-13-19 08:25AM  
May-07-19 10:38AM  
May-06-19 10:30AM  
Apr-28-19 10:51AM  
Apr-02-19 10:23PM  
Mar-28-19 07:00AM  
Mar-21-19 07:00AM  
Jan-04-19 06:15PM  
Jan-03-19 07:00AM  
Dec-20-18 07:00AM  
Dec-10-18 07:30AM  
Dec-08-18 09:58PM  
Dec-06-18 07:00AM  
Dec-02-18 09:00PM  
Dec-01-18 09:25PM  
Nov-12-18 05:55PM  
Nov-09-18 02:31PM  
Nov-06-18 08:01AM  
Nov-05-18 07:00AM  
Nov-01-18 09:01AM  
Sep-17-18 07:00AM  
Sep-07-18 07:00AM  
Aug-29-18 10:01PM  
Aug-13-18 04:05PM  
Aug-08-18 07:00AM  
Aug-06-18 07:00AM  
Jul-12-18 07:00AM  
Jun-25-18 07:00AM  
Jun-11-18 08:05AM  
May-14-18 07:00AM  
Apr-03-18 05:00PM  
Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.